AbbVie is looking to expand its presence in chronic lymphocytic leukemia (CLL) with new data on the Genmab-partnered CD20xCD3-directed bispecific antibody Epkinly (epcoritamab-bysp) in patients with relapsed/refractory disease.
The drug makers presented data from the expansion cohort of the Phase Ib/II EPCORE-CLL-1 trial in an oral presentation at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?